Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial
Keith D. Lindor, Kris V. Kowdley, E. Jenny Heathcote, M. Edwyn Harrison, Roberta Jorgensen, Paul Angulo, James F. Lymp, Lawrence Burgart, Patrick Colin – 27 February 2004 – No effective medical therapy is available for all patients with nonalcoholic steatohepatitis (NASH). Ursodeoxycholic acid (UDCA) has been suggested to be of benefit based on open label clinical studies. We randomized 166 patients with liver biopsy–proven NASH to receive between 13 and 15 mg/kg/d of UDCA or placebo for 2 years. End points included changes in liver test results and liver histology at 2 years of therapy.